180 related articles for article (PubMed ID: 34473708)
1. phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints.
Yin J; Du Y; Qin R; Shen S; Mandrekar S
PLoS One; 2021; 16(9):e0256391. PubMed ID: 34473708
[TBL] [Abstract][Full Text] [Related]
2. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
3. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
4. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
[TBL] [Abstract][Full Text] [Related]
5. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
7. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
Zang Y; Lee JJ; Yuan Y
Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841
[TBL] [Abstract][Full Text] [Related]
8. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
Silva RB; Yap C; Carvajal R; Lee SM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
[TBL] [Abstract][Full Text] [Related]
9. Accelerated titration designs for phase I clinical trials in oncology.
Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
[TBL] [Abstract][Full Text] [Related]
10. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
11. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
Chen Z; Krailo MD; Sun J; Azen SP;
Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.
Bagley EM; Wages NA
J Biopharm Stat; 2024 Mar; 34(2):151-163. PubMed ID: 36879525
[TBL] [Abstract][Full Text] [Related]
14. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding designs for cumulative toxicities using multiple constraints.
Lee SM; Ursino M; Cheung YK; Zohar S
Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
[TBL] [Abstract][Full Text] [Related]
17. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.
Zhou Y; Lin R; Kuo YW; Lee JJ; Yuan Y
JCO Clin Cancer Inform; 2021 Jan; 5():91-101. PubMed ID: 33439726
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; Thiébaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
19. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
[TBL] [Abstract][Full Text] [Related]
20. Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
Zang Y; Guo B; Qiu Y; Liu H; Opyrchal M; Lu X
Clin Trials; 2024 Jun; 21(3):298-307. PubMed ID: 38205644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
